Cumberland Pharmaceuticals announced Phase 2a trial results for its drug ifetroban in systemic sclerosis patients, showing safety but no clear efficacy. The small 41-patient study lacked power to prove treatment benefits, leading to a nearly 49% drop in stock price. This triggered an investigation by Pomerantz LLP into possible securities fraud or misconduct by the company and its executives. Investors are advised to contact the law firm for potential class action participation.
Cumberland Pharmaceuticals Inc. is the subject of this investor alert, with Pluang providing a snapshot of the health sector as of Nov 12, 2026 22:11 WIB. Among 150 priced health-sector US stocks, 42 rose and 108 fell today. Twist Bioscience Corp (TWST) saw a steep 12.99% drop to USD 106.67 with a typical hold time of 27 days and exclusively buy-side order activity, contrasting with 10X Genomics Inc (TXG) which fell 7.90% to USD 57.15 and had a longer hold time of 92 days with nearly balanced buy/sell orders, while Erasca Inc (ERAS) dropped 7.50% to USD 15.54 with a very short hold time of 4 days.
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
atQor has been named a finalist for the 2026 Microsoft Partner of the Year Award in the Agents category, recognized for its innovative and scalable agentic AI solutions deployed across nine industries. The company developed 252 AI agents in FY26, wit...
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
